drugset / Trial / NCT02246127
Sequentiality of Everolimus and STZ-5FU in Advanced Pancreatic Neuroendocrine Tumor
Phase 3
Completed
141 enrolled
Spanish Group for Research in Neuroendocrine Tumors
European Neuroendocrine Tumor Society · collabKantar Health · collabNovartis Pharmaceuticals · collab
RandomizedCrossoverOpen-labelTreatment
Summary
The purpose of this study is to compare streptozotocin (STZ) vs everolimus as first line treatment for advanced pNET and to elucidate which sequence of STZ based chemotherapy and the mammalian Target of Rapamycin (mTOR) inhibitor, everolimus, gives better results in terms of second Progression Free Survival (PFS) in well differentiated and advanced pancreatic NETs.
Timeline
- Start
- 2014-10-27
- Primary completion
- 2020-11-18
- Completion
- 2021-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Everolimus | Small molecule | 10 mg | Oral |
| Subject | fluorouracil | Small molecule | 400 mg/m2 | Other |
| Subject | fluorouracil | Small molecule | 1000 mg/m2 | Other |
| Subject | streptozocin | Small molecule | 500 mg/m2 | Other |